BioXcel Therapeutics Announces Reverse Stock SplitBioXcel Therapeutics, Inc. (NASDAQ:BTAI) has recently undertaken a significant corporate action by initiating a reverse stock split. The company filed an amendment to its Amended and Restated Certific

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BioXcel Therapeutics’s 8K filing here.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.